Immuneering (IMRX) analyst forecast and price target
Analyst forecast
Consensus of 7 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Initiated Coverage | Buy | $14.00 | Aug 6, 2026 |
| Needham | Maintained | Buy | $18.00 from $11.00 | Jul 20, 2026 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | — | Jul 8, 2026 |
| Chardan Capital | Maintained | Buy | $20.00 | May 19, 2026 |
| Needham | Maintained | Buy | $11.00 | Mar 9, 2026 |
| Chardan Capital | Maintained | Buy | $20.00 | Nov 13, 2025 |
| Leerink Partners | Initiated Coverage | Outperform | $15.00 | Oct 31, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $11.00 | Sep 30, 2025 |
| Chardan Capital | Maintained | Buy | $20.00 from $13.00 | Sep 26, 2025 |
| Oppenheimer | Maintained | Outperform | $30.00 from $21.00 | Sep 25, 2025 |
| Needham | Maintained | Buy | $11.00 from $8.00 | Sep 15, 2025 |
| Needham | Maintained | Buy | $8.00 | Aug 26, 2025 |
| Chardan Capital | Maintained | Buy | $13.00 | Aug 14, 2025 |
| Chardan Capital | Maintained | Buy | $13.00 | Jun 18, 2025 |
| Needham | Maintained | Buy | $9.00 | Jun 18, 2025 |
| Mizuho | Maintained | Outperform | $10.00 from $8.00 | Jun 18, 2025 |
| Needham | Maintained | Buy | $9.00 | Jun 5, 2025 |
| Oppenheimer | Maintained | Outperform | $21.00 from $25.00 | May 7, 2025 |
| Chardan Capital | Maintained | Buy | $13.00 | May 6, 2025 |
| Needham | Maintained | Buy | $12.00 | Apr 10, 2025 |
Frequently asked questions
Is IMRX a buy, sell, or hold?
Analysts covering Immuneering currently average a Buy rating: 7 buy, 0 hold and 0 sell, from 7 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on IMRX?
On Aug 6, 2026, HC Wainwright & Co. initiated coverage of Immuneering at Buy with a price target of $14.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.